

In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

Claims 1-25 (cancelled)

Claim 26 (previously presented): A method of treating cancer which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 27 (previously presented): A method for reducing abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 28 (previously presented): A method of inducing apoptosis in a cancerous cell which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 29 (previously presented): A method of providing an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 30 (previously presented): A method of providing an anti-angiogenic effect which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 31 (previously presented): The method according to claim 26 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate

cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.

Claim 32 (previously presented): The method according to claim 26 wherein the cancer is prostate cancer.

Claim 33 (previously presented): The method according to claim 26 wherein the cancer is SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer.

Claim 34 (previously presented): The method according to claim 26 wherein the cancer is bladder cancer, oesophageal cancer, gastric cancer, melanoma, cervical cancer and / or renal cancer.

Claim 35 (previously presented): The method according to claim 26 wherein the cancer is endometrial, liver, stomach, thyroid, rectal and / or brain cancer.

Claim 36 (previously presented): The method according to claim 26 wherein the cancer is SCLC.

Claim 37 (previously presented): The method according to claim 26 wherein the cancer is NSCLC.

Claim 38 (previously presented): The method according to claim 26 wherein the cancer is colorectal cancer.

Claim 39 (previously presented): The method according to claim 26 wherein the cancer is ovarian cancer.

Claim 40 (previously presented): The method according to claim 26 wherein the cancer is breast cancer.

Claim 41 (previously presented): The method according to claim 26 wherein the cancer is in a metastatic state.

Claim 42 (previously presented): The method according to claim 26 wherein the cancer is in a non-metastatic state.

Claim 43 (previously presented): The method according to claim 26 wherein the cancer is renal, thyroid, lung, breast or prostate cancer and is producing bone metastases.

Claim 44 (previously presented): A method of inhibiting bone metastases and inhibiting invasion which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 45 (previously presented): A method of inhibiting bone metastases which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 46 (previously presented): A method of preventing bone metastases which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 47 (previously presented): A method of treating bone metastases which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 48. (new) A method for the prevention or treatment of pain which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 49. (new) A method for the prevention or treatment of pain associated with elevated endothelin-1 production which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Claim 50. (new) A method for the prevention or treatment of pain associated with stimulation of the ET_A receptor which comprises administering an effective amount of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.